SAN DIEGO, March 28, 2017 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that its chief executive officer, Brian
Lian, Ph.D., will deliver a corporate presentation at H.C.
Wainwright & Co.'s 1st Annual NASH Investor
Conference, being held April 3, 2017
at the St. Regis Hotel in New York.
Details for this presentation are as follows:
- H.C. Wainwright & Co.'s 1st Annual NASH Investor
Conference – webcast available
Time/Date: 3:20 p.m. ET on
Monday, April 3, 2017
Location: St. Regis Hotel, New
York
Presentation Room: Versailles Room
To access the live webcast of Viking's presentation, please
visit "Webcasts & Presentations" within the News & Events
section of Viking's Investors page at www.vikingtherapeutics.com.
Additionally, a replay of the webcast will be available on the
Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on the
development of novel, first-in-class or best-in-class therapies for
metabolic and endocrine disorders. The company's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. Viking has exclusive worldwide rights to a portfolio
of five therapeutic programs in clinical trials or preclinical
studies, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated. The company's clinical programs
include VK5211, an orally available, non-steroidal selective
androgen receptor modulator, or SARM, in Phase 2 development for
the treatment and prevention of lean body mass loss in patients who
have undergone hip fracture surgery, VK2809, a small molecule
thyroid beta agonist in Phase 2 development for
hypercholesterolemia and fatty liver disease, and VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for type 2 diabetes. Viking is also developing
novel and selective agonists of the thyroid beta receptor for GSD
Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage
programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-hc-wainwright--cos-1st-annual-nash-investor-conference-300429997.html
SOURCE Viking Therapeutics, Inc.